AIM ImmunoTech Inc. (AIM) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, AIM ImmunoTech Inc.'s filing signal continuing negative.

AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders, with a particular emphasis on its flagship product, Ampligen (rintatolimod). The company is strategically concentrating its development efforts on late-stage pancreatic cancer, citing a significant unmet medical need and market opportunity, supported by broad combination therapy patents and orphan drug designations in the US and EU. Ampligen is also being investigated for its potential as an antiviral agent and for treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-COVID conditions. The company's other product, Alferon N Injection (Interferon alfa), is approved for treating certain types of warts but is not currently in active development.

Revenue is primarily generated from the Ampligen Cost Recovery Program, which saw a decrease in 2025 due to fluctuating patient participation. The company does not currently generate material revenue from operations and does not anticipate doing so in the near future.